American Society of Hematology

Figure 2.

$CMML monocyte addiction to MCL1. (A) iBH3 profiling: CD14+ peripheral blood monocytes collected from patients with CMML (n = 14-21) and healthy donors (n = 17-22) were incubated with the indicated peptides (80 μM) before measuring the flow of the fraction of cytochrome c released. (B) RT-qPCR analysis of indicated gene ex-pression in sorted peripheral blood monocytes collected from patients with CMML (n = 9-30) and healthy donors (n = 9-28) using PPIA as a housekeeping gene. (C) Peripheral blood monocytes from patients with CMML (n = 24-71) and healthy donors (n = 12-49) were treated with venetoclax (1 µM), navitoclax (100 nM), or S63845 (10 nM) for 24 hours at 37°C before measuring the fraction of AnV–/PI– cells by flow cytometry. (D) Immunoblot analysis of indicated proteins in sorted monocytes treated with indicated doses of S63845 for 24 hours. Data are shown as mean ± SEM. Mann-Whitney U test: *P < .05; **P < .01; ***P < .001. ns, not significant.$

CMML monocyte addiction to MCL1. (A) iBH3 profiling: CD14⁺ peripheral blood monocytes collected from patients with CMML (n = 14-21) and healthy donors (n = 17-22) were incubated with the indicated peptides (80 μM) before measuring the flow of the fraction of cytochrome c released. (B) RT-qPCR analysis of indicated gene ex-pression in sorted peripheral blood monocytes collected from patients with CMML (n = 9-30) and healthy donors (n = 9-28) using PPIA as a housekeeping gene. (C) Peripheral blood monocytes from patients with CMML (n = 24-71) and healthy donors (n = 12-49) were treated with venetoclax (1 µM), navitoclax (100 nM), or S63845 (10 nM) for 24 hours at 37°C before measuring the fraction of AnV^–/PI^– cells by flow cytometry. (D) Immunoblot analysis of indicated proteins in sorted monocytes treated with indicated doses of S63845 for 24 hours. Data are shown as mean ± SEM. Mann-Whitney U test: *P < .05; **P < .01; ***P < .001. ns, not significant.

This Feature Is Available To Subscribers Only